Mogrify Competitors

Incyte is focused on advancing biopharmaceutical innovation. Founded in 2002 with a small number of scientists, chemists and biologists in Wilmington, Delaware, Incyte has grown into a global organization with a robust portfolio of treatments across Hematology, Oncology and Inflammation and Autoimmunity. Today, the company has more than 2,800 employees and operations in 13 countries across North America, Europe and Asia. Our goal is to develop breakthrough medicines that improve patients' lives. With patients at the center of everything we do, our discovery approach focuses on building a portfolio of compounds that are scientifically differentiated and poised to make a meaningful impact. At Incyte, we aim to foster a workplace grounded in respect, curiosity and accountability. We are proud to have been named among the Top Employers by Science magazine for 8 consecutive years, as well as being named one of the Global Top 100 Most Loved Workplaces and America’s Top 100 Most Loved Workplaces by Newsweek and the Best Practice Institute. To learn more, visit Incyte.com and Investor.Incyte.com. Follow us on social media: LinkedIn, X, Instagram, Facebook, YouTube. See our Community Guidelines: http://bit.ly/2sV0H5W

Acelity is a global advanced wound care company, offering innovative solutions from the hospital to home that improve the lives of patients in more than 90 countries. Our mission is to change the practice of medicine with solutions that speed healing, create economic value and improve patients’ lives. Our shared values drive our company’s personality, culture and priorities by providing a framework for making decision: Customer First, Integrity, A Will to Win, One Acelity. We are the undisputed leader in negative pressure wound therapy and the market leader in collagen dressings. Acelity is headquartered in San Antonio, Texas, with nearly 5,000 employees around the globe. This channel and specific content are intended for a global audience. Patients should consult with their healthcare providers regarding their specific medical conditions, treatments, information on this channel, and risks and benefits of Acelity products. This channel is not a substitute for professional medical advice, diagnosis, or treatment. Not all Acelity products are available in all countries. Acelity is not responsible for, and does not control/endorse materials such as linked 3rd party videos, sites or ads, and makes no representations regarding their accuracy.

bluebird bio has rebranded as Genetix Biotherapeutics, returning to our foundational roots and renewing our commitment to delivering transformative genetic therapies for patients living with sickle cell disease, β-thalassemia, and cerebral adrenoleukodystrophy. Follow our new page at the link below!